Navigation Links
AACR Data Highlights InNexus Preclinical Antibody Candidate
Date:4/9/2009

- Additional Presentations Underscore Potency, Binding Capabilities for Antibody Pipeline And Novel Technologies -

SCOTTSDALE, Ariz., April 9 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. (Toronto Stock Exchange: IXS.V, http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL(TM)), announced today that the company will be presenting new data on its lead preclinical candidate DXL625 (CD20) for the prospective treatment of Non Hodgkin's Lymphoma (NHL) at the annual meeting of the American Association for Cancer Research (AACR), April 18-22, in Denver.

"Preclinical data on DXL625 indicates the strong promise of this candidate as a prospective treatment for NHL and Chronic Lymphatic Leukemia (CLL), and we anticipate starting clinical trials in the near term," said Dr. Thomas Kindt, Chief Scientific Officer of InNexus. "The AACR will also feature a scientific presentation on our novel, proprietary approach for creating 'programmed' self-binding properties into antibodies. The increased potency of the antibody resulting from this technique suggests a new way to enhance antibody performance."

Jeff Morhet, Chairman and Chief Executive Officer of InNexus, said, "InNexus has executed a focused and accelerated development plan for DXL625, while efficiently discovering promising new therapeutic candidates and supportive technologies. InNexus remains a novel, and independent, 'pure-play' antibody development company--an unusual investment and commercial opportunity."

InNexus' AACR presentations are titled, "A Novel High Avidity Anti-CD20 With Markedly Increased Cytotoxicity Shows No Systemic Toxicity In The Cynomolgus Monkey At A Dose 100-Fold Above The Anticipated Therapeutic Dose", (AACR# 1231) and "Oxidative Modification Of An Anti-CD20 Antibody Imparts Autophilic Binding Kinetics", (AACR# 1230). Posters and company representatives will also be available within the AACR Antibody and Antibody Targets Session from 1:00-5:00 PM on April 19th in Hall B-F, Poster Section 12. The posters will also be available via the InNexus website beginning April 19th.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, which may cause actual results or performance to differ materially from those currently anticipated in such statements.


'/>"/>
SOURCE InNexus Biotechnology Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots
2. American Academy Of Orthopaedic Surgeons 2009 Annual Meeting Highlights and Hot Topics
3. February 2009 Mayo Clinic Womens HealthSource Highlights Diabetes and Heart Disease, Going Vegetarian and Tinnitus
4. Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
5. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
6. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
7. Symposium Highlights Yale Study Indicating Role of AHCC(R) for Immune System Enhancement and as a Promising Cancer Preventative
8. September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging
9. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
10. August 2008 Mayo Clinic Womens HealthSource Highlights Avoiding Blood Pressure Increase at Menopause, Healthful Benefits of Dark Chocolate and Scheduling a Colorectal Exam
11. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... , May 23, 2016 Diplomat Pharmacy, Inc. (NYSE: ... Fellowship and Internship programs. The hands-on learning experience is ... The full-time, paid Fellowship and Internship ... . Fellows and interns are provided optional housing ... Flint at the Riverfront Residence Hall to ...
(Date:5/23/2016)... The World Health Organization (WHO) expanded the Intended ... adolescents aged 13 years, and above. Effective immediately, the PrePex ... and adolescent males in the 14 priority countries in Southern ... first male circumcision device to receive WHO Prequalification on 31 ... said: " The expanded use of PrePex ...
(Date:5/23/2016)... 2016 The global  reprocessed medical ... by 2022, according to a new study by Grand ... coupled with the lack of centralized support for waste ... the demand for reprocessed medical devices market. Additionally, the ... that of the original device is the high impact ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... ... the perfect data logger for each job, ensuring the best suited solution to ... of MadgeTech data loggers at their lab in Istanbul. , Metroloji Okulu specializes ...
(Date:5/24/2016)... ... May 24, 2016 , ... American ... (Jon) Otterstatter to its board of directors. Otterstatter is co-founder, president and ... development of technological innovations that lead to broad-based healthcare solutions. , “Jon knows ...
(Date:5/24/2016)... ... 2016 , ... WaterAid launched the #perioddrama campaign to mark Menstrual Hygiene Day on ... around the world who do not have access to a toilet, even when they’re on ... dread of #perioddrama. The (sometimes hilarious) results help shine a light on the awkwardness that ...
(Date:5/24/2016)... ... 24, 2016 , ... Aloria Health Announces Opening of Eating ... , Aloria Health, specializing in a re-imagined, client-oriented approach to the treatment of ... treatment facility for outpatient, day treatment and residential care. Aloria Milwaukee will open ...
(Date:5/24/2016)... ... May 24, 2016 , ... Global Lyme ... education, today announced that it has named Scott Santarella as its new CEO. ... Lung Cancer Foundation (ALCF) in San Francisco, where he successfully helped to grow ...
Breaking Medicine News(10 mins):